ArriVent Inventory vs Total Stockholder Equity Analysis

AVBP Stock

29.96 0.85 2.92%

ArriVent BioPharma, financial indicator trend analysis is way more than just evaluating ArriVent BioPharma, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ArriVent BioPharma, is a good investment. Please check the relationship between ArriVent BioPharma, Inventory and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ArriVent BioPharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Inventory vs Total Stockholder Equity

Inventory vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ArriVent BioPharma, Inventory account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between ArriVent BioPharma,'s Inventory and Total Stockholder Equity is 0.62. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of ArriVent BioPharma, Common, assuming nothing else is changed. The correlation between historical values of ArriVent BioPharma,'s Inventory and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of ArriVent BioPharma, Common are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Inventory i.e., ArriVent BioPharma,'s Inventory and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Inventory

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from ArriVent BioPharma,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ArriVent BioPharma, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ArriVent BioPharma, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

As of 12/01/2024, Selling General Administrative is likely to drop to about 7 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 38.4 M

ArriVent BioPharma, fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt	Inventory
Total Assets		0.97	0.97	1.0	-0.98	-0.89	0.97	1.0	0.78	0.77	-0.53	1.0	0.93	-0.65	0.78	0.87	0.97	-0.89	1.0	-0.99	1.0	-0.53	0.79	0.63	0.75	0.63
Other Current Liab	0.97		1.0	0.96	-0.93	-0.94	1.0	0.97	0.87	0.86	-0.54	0.97	0.99	-0.69	0.87	0.96	1.0	-0.94	0.96	-0.96	0.96	-0.54	0.91	0.7	0.85	0.71
Total Current Liabilities	0.97	1.0		0.96	-0.93	-0.94	1.0	0.97	0.87	0.86	-0.53	0.97	0.99	-0.69	0.87	0.96	1.0	-0.94	0.96	-0.96	0.96	-0.53	0.91	0.7	0.85	0.7
Total Stockholder Equity	1.0	0.96	0.96		-0.98	-0.88	0.96	1.0	0.78	0.76	-0.53	1.0	0.93	-0.64	0.77	0.86	0.96	-0.89	1.0	-0.99	1.0	-0.53	0.77	0.62	0.74	0.62
Net Debt	-0.98	-0.93	-0.93	-0.98		0.9	-0.93	-0.98	-0.78	-0.76	0.55	-0.98	-0.89	0.65	-0.77	-0.81	-0.93	0.9	-0.98	0.99	-0.99	0.55	-0.73	-0.55	-0.68	-0.54
Retained Earnings	-0.89	-0.94	-0.94	-0.88	0.9		-0.94	-0.9	-0.97	-0.96	0.69	-0.9	-0.94	0.82	-0.96	-0.93	-0.94	1.0	-0.89	0.93	-0.88	0.69	-0.92	-0.69	-0.85	-0.68
Accounts Payable	0.97	1.0	1.0	0.96	-0.93	-0.94		0.97	0.87	0.86	-0.53	0.97	0.99	-0.68	0.86	0.96	1.0	-0.94	0.96	-0.95	0.96	-0.53	0.91	0.69	0.84	0.69
Cash	1.0	0.97	0.97	1.0	-0.98	-0.9	0.97		0.79	0.78	-0.53	1.0	0.94	-0.65	0.79	0.88	0.97	-0.9	1.0	-0.99	1.0	-0.53	0.8	0.64	0.76	0.64
Non Current Assets Total	0.78	0.87	0.87	0.78	-0.78	-0.97	0.87	0.79		1.0	-0.79	0.79	0.9	-0.91	1.0	0.92	0.87	-0.97	0.78	-0.84	0.77	-0.79	0.94	0.8	0.93	0.79
Non Currrent Assets Other	0.77	0.86	0.86	0.76	-0.76	-0.96	0.86	0.78	1.0		-0.79	0.78	0.89	-0.91	1.0	0.92	0.86	-0.96	0.76	-0.82	0.75	-0.79	0.94	0.8	0.93	0.79
Other Assets	-0.53	-0.54	-0.53	-0.53	0.55	0.69	-0.53	-0.53	-0.79	-0.79		-0.53	-0.54	0.97	-0.79	-0.58	-0.53	0.69	-0.53	0.61	-0.53	1.0	-0.59	-0.82	-0.77	-0.8
Cash And Short Term Investments	1.0	0.97	0.97	1.0	-0.98	-0.9	0.97	1.0	0.79	0.78	-0.53		0.94	-0.65	0.79	0.88	0.97	-0.9	1.0	-0.99	1.0	-0.53	0.8	0.64	0.76	0.64
Net Receivables	0.93	0.99	0.99	0.93	-0.89	-0.94	0.99	0.94	0.9	0.89	-0.54	0.94		-0.7	0.89	0.99	0.99	-0.94	0.93	-0.92	0.92	-0.54	0.95	0.73	0.89	0.74
Common Stock Shares Outstanding	-0.65	-0.69	-0.69	-0.64	0.65	0.82	-0.68	-0.65	-0.91	-0.91	0.97	-0.65	-0.7		-0.91	-0.74	-0.69	0.82	-0.64	0.72	-0.64	0.97	-0.76	-0.87	-0.88	-0.85
Other Current Assets	0.78	0.87	0.87	0.77	-0.77	-0.96	0.86	0.79	1.0	1.0	-0.79	0.79	0.89	-0.91		0.92	0.87	-0.96	0.77	-0.83	0.76	-0.79	0.94	0.8	0.93	0.79
Other Stockholder Equity	0.87	0.96	0.96	0.86	-0.81	-0.93	0.96	0.88	0.92	0.92	-0.58	0.88	0.99	-0.74	0.92		0.96	-0.93	0.86	-0.86	0.85	-0.58	0.99	0.8	0.94	0.8
Total Liab	0.97	1.0	1.0	0.96	-0.93	-0.94	1.0	0.97	0.87	0.86	-0.53	0.97	0.99	-0.69	0.87	0.96		-0.94	0.96	-0.95	0.96	-0.53	0.91	0.7	0.85	0.7
Net Invested Capital	-0.89	-0.94	-0.94	-0.89	0.9	1.0	-0.94	-0.9	-0.97	-0.96	0.69	-0.9	-0.94	0.82	-0.96	-0.93	-0.94		-0.89	0.93	-0.88	0.69	-0.92	-0.69	-0.85	-0.68
Total Current Assets	1.0	0.96	0.96	1.0	-0.98	-0.89	0.96	1.0	0.78	0.76	-0.53	1.0	0.93	-0.64	0.77	0.86	0.96	-0.89		-0.99	1.0	-0.53	0.78	0.63	0.74	0.63
Capital Stock	-0.99	-0.96	-0.96	-0.99	0.99	0.93	-0.95	-0.99	-0.84	-0.82	0.61	-0.99	-0.92	0.72	-0.83	-0.86	-0.95	0.93	-0.99		-0.99	0.61	-0.79	-0.63	-0.76	-0.62
Net Working Capital	1.0	0.96	0.96	1.0	-0.99	-0.88	0.96	1.0	0.77	0.75	-0.53	1.0	0.92	-0.64	0.76	0.85	0.96	-0.88	1.0	-0.99		-0.53	0.77	0.62	0.73	0.62
Common Stock	-0.53	-0.54	-0.53	-0.53	0.55	0.69	-0.53	-0.53	-0.79	-0.79	1.0	-0.53	-0.54	0.97	-0.79	-0.58	-0.53	0.69	-0.53	0.61	-0.53		-0.59	-0.82	-0.77	-0.8
Short Long Term Debt Total	0.79	0.91	0.91	0.77	-0.73	-0.92	0.91	0.8	0.94	0.94	-0.59	0.8	0.95	-0.76	0.94	0.99	0.91	-0.92	0.78	-0.79	0.77	-0.59		0.78	0.94	0.79
Current Deferred Revenue	0.63	0.7	0.7	0.62	-0.55	-0.69	0.69	0.64	0.8	0.8	-0.82	0.64	0.73	-0.87	0.8	0.8	0.7	-0.69	0.63	-0.63	0.62	-0.82	0.78		0.95	1.0
Short Term Debt	0.75	0.85	0.85	0.74	-0.68	-0.85	0.84	0.76	0.93	0.93	-0.77	0.76	0.89	-0.88	0.93	0.94	0.85	-0.85	0.74	-0.76	0.73	-0.77	0.94	0.95		0.95
Inventory	0.63	0.71	0.7	0.62	-0.54	-0.68	0.69	0.64	0.79	0.79	-0.8	0.64	0.74	-0.85	0.79	0.8	0.7	-0.68	0.63	-0.62	0.62	-0.8	0.79	1.0	0.95

Click cells to compare fundamentals

ArriVent BioPharma, Account Relationship Matchups

Pair Trading with ArriVent BioPharma,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma, will appreciate offsetting losses from the drop in the long position's value.

Moving together with ArriVent Stock

0.61	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.67	EWTX	Edgewise Therapeutics	Pair Corr

Moving against ArriVent Stock

0.74	HLN	Haleon plc	Pair Corr
0.68	ZTS	Zoetis Inc	Pair Corr
0.66	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.54	TAK	Takeda Pharmaceutical	Pair Corr
0.5	ELAN	Elanco Animal Health	Pair Corr

The ability to find closely correlated positions to ArriVent BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma, Common to buy it.

The correlation of ArriVent BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ArriVent BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ArriVent Stock Analysis

When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC